ROBERT E. CONWAY - 15 Dec 2022 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)

Role: Director, Chairman of the Board
Signature: /s/ C. Jeffrey Dekker, Attorney-in-Fact
Issuer symbol: ORKA
Transactions as of: 15 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 19 Dec 2022, 15:20:06 UTC
Previous filing: 04 Jan 2022
Next filing: 05 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABIO	Common Stock						50,000	15 Dec 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABIO	Stock Option (right to buy)	Award	$0	+6,000		$0.000000	6,000	15 Dec 2022	Common Stock	6,000	$2.32	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of December 15, 2022. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.